UY28200A1 - Acidos carboxílicos de heteroarilo condensado como agonistas del ppar - Google Patents

Acidos carboxílicos de heteroarilo condensado como agonistas del ppar

Info

Publication number
UY28200A1
UY28200A1 UY28200A UY28200A UY28200A1 UY 28200 A1 UY28200 A1 UY 28200A1 UY 28200 A UY28200 A UY 28200A UY 28200 A UY28200 A UY 28200A UY 28200 A1 UY28200 A1 UY 28200A1
Authority
UY
Uruguay
Prior art keywords
carboxylic acids
condensed
heteroarilo
ppar agonists
ppar
Prior art date
Application number
UY28200A
Other languages
English (en)
Inventor
Wei-Guo Su
Luke Raymond Zehnder
Donald James Skalitzky
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY28200A1 publication Critical patent/UY28200A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Ácidos carboxílicos de heteroarilo condensado de fórmula (i): en la que R1, Ar,A, Y, HET, Q y T son como se han definido en la memoria descriptiva; composiciones farmacéuticas que contienen cantidades eficaces de dichos compuestos o sus sales son útiles para tratar trastornos relativos a PPAR, tales como diabetes, dislipidemia, obesidad y trastornos inflamatorios.
UY28200A 2003-02-21 2004-02-19 Acidos carboxílicos de heteroarilo condensado como agonistas del ppar UY28200A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44893103P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
UY28200A1 true UY28200A1 (es) 2004-09-30

Family

ID=32908672

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28200A UY28200A1 (es) 2003-02-21 2004-02-19 Acidos carboxílicos de heteroarilo condensado como agonistas del ppar

Country Status (14)

Country Link
US (1) US20040209929A1 (es)
EP (1) EP1597257A1 (es)
JP (1) JP2006518366A (es)
AR (1) AR044498A1 (es)
BR (1) BRPI0407735A (es)
CA (1) CA2516475A1 (es)
GT (1) GT200400019A (es)
MX (1) MXPA05008922A (es)
NL (1) NL1025542C2 (es)
PA (1) PA8594401A1 (es)
PE (1) PE20050223A1 (es)
TW (1) TW200424201A (es)
UY (1) UY28200A1 (es)
WO (1) WO2004074284A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1692506A4 (en) * 2003-11-17 2008-01-09 Janssen Pharmaceutica Nv MODELING A SYSTEMIC INFLAMMATORY RESPONSE TO INFECTION
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
ES2343640T3 (es) * 2004-08-12 2010-08-05 Amgen Inc. Bisaril-sulfonamidas.
CN101018790A (zh) * 2004-09-11 2007-08-15 塞诺菲-安万特德国有限公司 7-氮杂吲哚以及其用作ppar激动剂的应用
US8003806B2 (en) 2004-11-12 2011-08-23 OSI Pharmaceuticals, LLC Integrin antagonists useful as anticancer agents
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
CA2740366A1 (en) * 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
JP6369951B2 (ja) * 2015-08-26 2018-08-08 三井農林株式会社 ジペプチジルペプチダーゼ−iv阻害剤
WO2017121308A1 (en) * 2016-01-11 2017-07-20 Chongqing Fochon Pharmaceutical Co., Ltd. Fused pyridine compounds, compositions and methods of use
WO2018202039A1 (zh) * 2017-05-03 2018-11-08 成都海创药业有限公司 杂环化合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
KR100356551B1 (ko) * 1994-10-20 2002-12-18 닛뽕 케미파 가부시키가이샤 퀴놀린유도체
AU782631C (en) * 1999-12-03 2006-08-17 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
EP1405848B1 (en) * 2001-06-18 2008-05-07 Ono Pharmaceutical Co., Ltd. Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
EA200400140A1 (ru) * 2001-08-29 2004-08-26 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Пероральные противодиабетические агенты
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents

Also Published As

Publication number Publication date
CA2516475A1 (en) 2004-09-02
AR044498A1 (es) 2005-09-14
PA8594401A1 (es) 2004-09-16
JP2006518366A (ja) 2006-08-10
NL1025542C2 (nl) 2005-10-11
NL1025542A1 (nl) 2004-08-24
TW200424201A (en) 2004-11-16
PE20050223A1 (es) 2005-03-22
US20040209929A1 (en) 2004-10-21
GT200400019A (es) 2004-09-21
EP1597257A1 (en) 2005-11-23
WO2004074284A1 (en) 2004-09-02
MXPA05008922A (es) 2005-10-05
BRPI0407735A (pt) 2006-02-14

Similar Documents

Publication Publication Date Title
ECSP056105A (es) Acidos carboxilicos alfa sustituidos como moduladores ppar
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
PE20121499A1 (es) Formas cristalinas de 3-(2, 6-dicloro-3, 5-dimetoxi-fenil)-1-{6-4[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
CL2008002159A1 (es) Compuestos derivados de n-(((1r, 4r)-4-aminociclohexil)metil) sulfonaminas sustituidas con heterociclos, antagonistas del receptor npy y5; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar anorexia y obesidad.
EA200901609A1 (ru) Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов
EA201100877A1 (ru) Спирогетероциклические n-оксиамиды в качестве пестицидов
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
ATE459352T1 (de) Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe
ATE500222T1 (de) Benzamid- und heteroarenderivate als cetp- inhibitoren
UY28200A1 (es) Acidos carboxílicos de heteroarilo condensado como agonistas del ppar
CL2008003472A1 (es) Compuestos derivados de 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-ona, proceso para la preparacion de los mismos, compuestos intermediarios, composicion farmaceutica que comprende dicho compuesto; combinacion farmaceutica, y sus usos en el tratamiento de enfermedades inflamatorias.
UA106880C2 (uk) Нові гербіциди
CL2011003138A1 (es) N-(protegido- n-(3-metoxi-5-metilpirazon-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridino-3-sulfonamida y su proceso de preparacion.
EA201170828A1 (ru) Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза
DE502007006315D1 (de) 1,3-disubstituierte 4-methyl-1 h-pyrrol-2-carbonsärzneimitteln
GT200700105A (es) Inhibidor del factor xa
AR108389A2 (es) Derivados de ácido fenilacético
DE602005014629D1 (de) Pyrazolphenylderivate als ppar-aktivatoren
UY31448A1 (es) Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3.
ATE525370T1 (de) Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten
DOP2004000813A (es) Carboxilicos de heteroarilo condensado como agonistas del ppar
EA201101014A1 (ru) Сульфонамиды, предназначенные для лечения респираторных нарушений

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140610